Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > BUSINESS
BUSINESS
- Astellas, Affinivax Ink Global Partnership on Pneumococcal Vaccine
March 1, 2017
- Novo Files Once-Weekly GLP-1 in Japan
March 1, 2017
- Tolero Aims to File for AML Treatment Alvocidib in FY2018 in US: Sumitomo Dainippon
March 1, 2017
- Takeda to Transfer Part of CMC Functions to Bushu
March 1, 2017
- Kyowa Earns Rights for Astellas’ Extended-Release Quetiapine
February 28, 2017
- Shionogi to Comarket Methapain with Terumo
February 28, 2017
- Alecensa Gets Approval in Taiwan: Chugai
February 28, 2017
- Sanofi Files Atopic Dermatitis Treatment Dupilumab in Japan
February 28, 2017
- LEO Pharma Applies for Gel Formulation for Dovobet
February 28, 2017
- Daiichi Sankyo to Set Up Brand Strategy Unit to Spur Cancer Biz
February 27, 2017
- Eisai’s Yuji Matsue to Spearhead EA Pharma
February 27, 2017
- Daiichi Sankyo Takes Aim at Top Spot in Japan Ethical Drug Market: Next President
February 27, 2017
- Koichi Shimada to Lead Alfresa Pharma
February 24, 2017
- Takeda, Astellas to Build Joint Storage and Distribution System in Hokkaido
February 24, 2017
- JCR to Develop Pompe Disease Treatment Using Blood-Brain Barrier Technology
February 24, 2017
- Kyorin Holdings to Set Up Office in Indonesia
February 23, 2017
- Takeda Assigns High-Caliber Staffers for Govt’s Community-Based Care Initiative
February 22, 2017
- Generic Picks Will Depend on Regions as Joint Purchase Gets Underway, Iwasaki Says on Teva JV
February 22, 2017
- Debiopharm Takes Nippon Kayaku to Supreme Court over Elplat
February 22, 2017
- With Positive PIII Data, AZ Aims for Olaparib’s Japan Approval in 2018
February 22, 2017
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…